Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.72)
# 156
Out of 5,182 analysts
140
Total ratings
56.69%
Success rate
45.36%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGNX MacroGenics | Upgrades: Buy | $3 → $9 | $3.01 | +199.00% | 3 | Apr 10, 2026 | |
| TBPH Theravance Biopharma | Maintains: Neutral | $14 → $17 | $16.76 | +1.43% | 3 | Apr 7, 2026 | |
| HROW Harrow | Reiterates: Buy | $74 → $65 | $40.48 | +60.57% | 5 | Apr 7, 2026 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $3 → $4 | $1.56 | +156.41% | 3 | Mar 25, 2026 | |
| CLYM Climb Bio | Initiates: Buy | $26 | $9.26 | +180.78% | 1 | Mar 24, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Buy | $22 | $8.87 | +148.03% | 3 | Mar 18, 2026 | |
| NKTR Nektar Therapeutics | Reiterates: Buy | $105 → $150 | $83.81 | +78.98% | 4 | Feb 23, 2026 | |
| CYTK Cytokinetics | Maintains: Buy | $90 → $108 | $60.69 | +77.95% | 6 | Jan 21, 2026 | |
| IRD Opus Genetics | Initiates: Buy | $9 | $5.00 | +80.00% | 1 | Dec 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $42 | $39.46 | +6.44% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 → $40 | $27.94 | +43.19% | 2 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.56 | +163.16% | 1 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 → $16 | $7.92 | +102.02% | 20 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $560 | $516.69 | +8.38% | 13 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $55 | $34.58 | +59.05% | 14 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.90 | +589.66% | 1 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $18 | $2.74 | +556.93% | 10 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.36 | +267.65% | 2 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 → $20 | $13.84 | +44.51% | 3 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 → $35 | $20.06 | +74.48% | 2 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 → $38 | $70.13 | -45.81% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $32.39 | +196.39% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $1.28 | +17.19% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $6.90 | +1,928.99% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $4.12 | +2,087.12% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $3.89 | +4,013.11% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.85 | +170.27% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $2.24 | +3,917.86% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $1.40 | +400.00% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $0.75 | +596,716.98% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.58 | +170,786.08% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $0.59 | +244,340.67% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $2.32 | +72.41% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $86.04 | -54.67% | 2 | Mar 18, 2020 |
MacroGenics
Apr 10, 2026
Upgrades: Buy
Price Target: $3 → $9
Current: $3.01
Upside: +199.00%
Theravance Biopharma
Apr 7, 2026
Maintains: Neutral
Price Target: $14 → $17
Current: $16.76
Upside: +1.43%
Harrow
Apr 7, 2026
Reiterates: Buy
Price Target: $74 → $65
Current: $40.48
Upside: +60.57%
Lineage Cell Therapeutics
Mar 25, 2026
Maintains: Buy
Price Target: $3 → $4
Current: $1.56
Upside: +156.41%
Climb Bio
Mar 24, 2026
Initiates: Buy
Price Target: $26
Current: $9.26
Upside: +180.78%
Arcturus Therapeutics Holdings
Mar 18, 2026
Initiates: Buy
Price Target: $22
Current: $8.87
Upside: +148.03%
Nektar Therapeutics
Feb 23, 2026
Reiterates: Buy
Price Target: $105 → $150
Current: $83.81
Upside: +78.98%
Cytokinetics
Jan 21, 2026
Maintains: Buy
Price Target: $90 → $108
Current: $60.69
Upside: +77.95%
Opus Genetics
Dec 10, 2025
Initiates: Buy
Price Target: $9
Current: $5.00
Upside: +80.00%
Centessa Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $33 → $42
Current: $39.46
Upside: +6.44%
Nov 21, 2025
Reiterates: Buy
Price Target: $30 → $40
Current: $27.94
Upside: +43.19%
Nov 19, 2025
Initiates: Buy
Price Target: $12
Current: $4.56
Upside: +163.16%
Nov 10, 2025
Reiterates: Buy
Price Target: $18 → $16
Current: $7.92
Upside: +102.02%
Sep 29, 2025
Maintains: Buy
Price Target: $460 → $560
Current: $516.69
Upside: +8.38%
Sep 17, 2025
Maintains: Buy
Price Target: $53 → $55
Current: $34.58
Upside: +59.05%
Aug 26, 2025
Initiates: Buy
Price Target: $20
Current: $2.90
Upside: +589.66%
Aug 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $2.74
Upside: +556.93%
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.36
Upside: +267.65%
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $13.84
Upside: +44.51%
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $20.06
Upside: +74.48%
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $70.13
Upside: -45.81%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $32.39
Upside: +196.39%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $1.28
Upside: +17.19%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $6.90
Upside: +1,928.99%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $4.12
Upside: +2,087.12%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $3.89
Upside: +4,013.11%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.85
Upside: +170.27%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $2.24
Upside: +3,917.86%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $1.40
Upside: +400.00%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $0.75
Upside: +596,716.98%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.58
Upside: +170,786.08%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $0.59
Upside: +244,340.67%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $2.32
Upside: +72.41%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $86.04
Upside: -54.67%